Press Room
  Date Title View
Nov 19, 1999
San Mateo, CA, November 19, 1999 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced the appointment of Craig R. Olson as Regional Managing Director, Latin America and Kenneth R. Cowan as Regional Managing Director, Middle East for the Company's international subsidiary, SciClone Pharmaceuticals International, Ltd. Olson and Cowan become SciClone...
PDF
Jan 19, 2000
San Mateo, CA, January 19, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the completion of a $6,100,000 private placement with its largest institutional shareholder, The Brown Simpson Strategic Growth Funds. The newly acquired funds will be directed toward the distribution of ZADAXIN...
PDF
Jan 27, 2000
San Mateo, CA, January 27, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the start of a U.S. Phase 2 hepatitis B study using ZADAXIN, the Company's host immune system enhancer (h-ISE), in combination with lamivudine, an FDA-approved nucleoside analogue. The study, conducted at Loyola U...
PDF
Feb 3, 2000
San Mateo, CA, February 3, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced results for the fourth quarter and year ended December 31, 1999.For the year, the Company reported total revenue of $9,397,000, a 152% increase over the $3,725,000 reported for 1998. Sales of ZADAXINÃ’, the Company's host immune system enhancer (...
PDF
Feb 15, 2000
San Mateo, CA, February 15, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced plans to move forward with the next stage of its phase 2 development program for CPX, a novel PRT (protein repair therapy) for cystic fibrosis (CF). SciClone, working closely with scientists and clinical investig...
PDF
Feb 23, 2000
San Mateo, CA, February 23, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today at the 12th Annual Cruttenden Roth Growth Stock Conference that it has been awarded a $300,000 grant to study SCV-07, the Company's new immunomodulator, as a potential treatment for tuberculosis (TB), the most co...
PDF
Mar 1, 2000
San Mateo, CA, March 1, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today that a study published in the peer-reviewed European Journal of Immunology (March 2000, Volume 30, Issue 3) shows that ZADAXIN® (thymosin alpha 1) directly increases the immune sys...
PDF
Mar 13, 2000
Rome, Italy and San Mateo, CA, March 13, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) and Sigma-Tau S.p.A., the leading research-based Italian pharmaceutical company, announced today they have signed an expanded development and marketing partnership for ZADAXINÃ’, SciClone's host immune system enhance...
PDF
Mar 17, 2000
San Mateo, CA, March 17, 2000 - SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that ZADAXIN, the Company's lead immunotherapy, has been approved for marketing in Thailand, Laos and Malta. ZADAXIN now is approved for marketing in 19 countries, principally for treatment of hepatitis B and hepatit...
PDF
Mar 22, 2000
San Mateo, CA, March 22, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status to ZADAXIN®, SciClone's lead immunotherapy, for the treatment of hepatocellular carcinoma,...
PDF
1
...
NextLast